CABA vs. PROK, KROS, ORGO, GHRS, SIGA, SAGE, ARCT, MREO, TRML, and PHAT
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include ProKidney (PROK), Keros Therapeutics (KROS), Organogenesis (ORGO), GH Research (GHRS), SIGA Technologies (SIGA), Sage Therapeutics (SAGE), Arcturus Therapeutics (ARCT), Mereo BioPharma Group (MREO), Tourmaline Bio (TRML), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.
Cabaletta Bio vs.
Cabaletta Bio (NASDAQ:CABA) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
Cabaletta Bio received 82 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 72.00% of users gave Cabaletta Bio an outperform vote while only 57.14% of users gave ProKidney an outperform vote.
51.6% of ProKidney shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by company insiders. Comparatively, 41.5% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Cabaletta Bio and Cabaletta Bio both had 4 articles in the media. ProKidney's average media sentiment score of 0.84 beat Cabaletta Bio's score of 0.80 indicating that ProKidney is being referred to more favorably in the news media.
ProKidney is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.
Cabaletta Bio presently has a consensus target price of $24.38, indicating a potential upside of 919.87%. ProKidney has a consensus target price of $4.50, indicating a potential upside of 172.73%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than ProKidney.
ProKidney's return on equity of 0.00% beat Cabaletta Bio's return on equity.
Cabaletta Bio has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
Summary
Cabaletta Bio and ProKidney tied by winning 7 of the 14 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
This page (NASDAQ:CABA) was last updated on 2/1/2025 by MarketBeat.com Staff
